CONV: round 1 — no prior position to converge with | SANDING: None
DROPPED(0): 
NEW(14): F-001, F-002, F-003, F-004, F-005, F-006, F-007, F-008, F-009, F-010, F-011, F-012, F-013, F-014

POSITION: Claude's position is directionally defensible but too generous: the draft has the right distinctive claims, yet several sentences still let the method inherit more experimental, follow-up, or independence weight than the evidence supports. The two-receipt distinction is explicitly stated in places, but hostile readers will attack the surrounding verbs and shorthand labels, especially 'supported chain,' 'true in fresh experimental data,' and claims about self-audit and UI automation.

F-001 [P0] correctness - The core 'follow-up' problem is not fully closed by retrospective adjudication
  EVID: Introduction lines 36-41 frame the missing step as asking whether each hypothesis is 'actually supported by data'; Background lines 28-31 contrasts time-slicing with whether a hypothesis is 'true in fresh experimental data.' But Section 2.2 lines 38-42 correctly says the referee queries pre-existing
  DO: Keep the triage-loop claim sharp, but explicitly say the method closes the triage/adjudication loop, not the experimental-follow-up loop. Replace 'true in fresh experimental data' with language about independent, pre-exi

F-002 [P1] correctness - The manuscript still leaks discovery language at the opening
  EVID: Introduction line 17 says 'where new discoveries wait, hidden in plain sight'; line 23 uses 'candidate discovery.' The user explicitly wants calibrated language and no unearned 'discovered/proven' framing.
  DO: Replace 'new discoveries wait' with 'candidate connections' or 'testable nominations.' 'Candidate discovery' is acceptable in classic LBD context only if immediately bounded as literature novelty, not biological truth.

F-003 [P0] correctness - Two-receipt distinction is stated, but later shorthand blurs it
  EVID: Introduction lines 46-50 correctly distinguishes experimental versus association receipts. But lines 63-69 say 'receipt-backed survivors,' 'support it as a Th1/Th2 regulator,' 'atopic-eczema link,' and 'including a falsification of its sharpest confounder' in one sentence. Methods line 84 asks wheth
  DO: Whenever 'full chain,' 'supported,' or 'disease-supported' appears near the disease hop, append a compact qualifier such as 'with the disease hop remaining GWAS-association evidence.' Make the STAT6 confounder language s

F-004 [P0] correctness - Open Targets novelty score is described as genetic-association evidence, but the code uses general associatedTargets scores
  EVID: Methods lines 30-32 says 'curated gene→disease genetic-association scores come from the Open Targets GraphQL API'; lines 50-52 call ac_known the 'Open Targets genetic-association score.' In src/arbiter/lbd/sources.py, the query reads disease.associatedTargets rows with target.approvedSymbol and scor
  DO: Separate the two concepts: T3 disease labels are genetic-association/module-enrichment receipts inherited from the source study; ac_known is an Open Targets target-disease association score used as a known-link/novelty p

F-005 [P1] correctness - The referee's 'confident no' is overstated because most funnel hops are preselected
  EVID: Methods lines 38-45 define A by knockdown QC, transcriptional effect, and Th1/Th2 significance before disease testing. Methods lines 91-96 admits only the program hop is tautological. src/arbiter/lbd/entities.py confirms A requires KD gate plus effect, and optionally program_significant; src/arbiter
  DO: Expand the honesty sentence in 3.3: within the generated funnel, KD and program are largely pre-gated, effect is partly pre-gated, and the large cull is disease-C specificity; the confident-no behavior is demonstrated by

F-006 [P1] correctness - 'Supported' terminology remains too strong for association-hop chains
  EVID: Methods lines 88-94 defines 'supported' for full chain and 'refuted-for-C'; stage1/sweep_Stim8hr.json uses referee_overall strings saying 'consistent with a validated gene -> program -> disease chain re-derived from the tables.' The manuscript says language was calibrated, but the primary artifact s
  DO: Do not claim the platform removed overstated language from all output unless the emitted artifacts are also cleaned or clearly scoped. In the manuscript, define 'supported' as a verdict label with bounded semantics, and 

F-007 [P1] correctness - Self-audit independence is carefully bounded, but 'The platform checked its own work' is rhetorically vulnerable
  EVID: Introduction lines 56-60 culminates in 'The platform checked its own work.' Background lines 72-78 gives the better qualified version: role, model, and checkpoint independence within one model family, with cross-vendor replication external.
  DO: Keep the independent critic-model claim, but avoid the slogan or immediately attach the boundary: role/model/checkpoint independence within one family, with cross-family replication external.

F-008 [P1] novelty - No-API headless automation is distinctive but currently reads as security-bypassing rather than reproducibility engineering
  EVID: Methods lines 106-117 says the driver loads an authenticated session and auto-approves working-directory, code-execution, and network-access prompts for unattended operation, then calls this 'principled UI automation' and 'the honest substitute.'
  DO: Keep the no-API/headless UI automation claim, but add the missing guardrails: fixed workspace, saved authenticated session owned by the operator, logged prompt approvals, bounded network/cache modes, and why unattended a

F-009 [P1] correctness - The grant identifier appears despite the stated author decision not to name it
  EVID: Background line 28 names '(NIH 1R01LM015392-01).' The prompt states the grant number is deliberately not named and should not be treated as an omission.
  DO: Remove the grant number from manuscript prose while retaining the verbatim quote and 'proposal submitted for funding consideration' framing.

F-010 [P2] correctness - The Background under-motivates why a held Perturb-seq substrate is the right alternative to time-slicing
  EVID: Background lines 28-31 says standard evaluations do not test truth in fresh data; Section 2.2 lines 36-45 introduces the held substrate. The transition asserts the need but does not explain why this substrate is a fair or limited adjudicator for LBD hypotheses.
  DO: Add a reviewer-proofing sentence: the substrate is not a universal truth oracle; it is a bounded, independent adjudication surface for mechanistic T-cell claims, useful precisely because it can return support/refutation/

F-011 [P2] correctness - The 'answer-free' universe is defensible but may sound stronger than it is
  EVID: Methods lines 36-43 says A is defined before disease information and cannot be contaminated by the answer. That is true for T3 disease labels, but A is selected on the same program and effect evidence later used by the referee.
  DO: Say 'disease-answer-free' or 'T3-free' rather than broad 'answer-free' when discussing A. Preserve the point that disease labels are not consulted, but do not imply independence from all later hop receipts.

F-012 [P2] correctness - The methods do not justify the ranking objective enough for a metrics audience
  EVID: Methods lines 57-70 gives the formula and says it was designed offline, with its structure fixed before running. It does not explain sensitivity, alternatives, or why the chosen weights beta=1, w=1, w2=3 are not tuned to NAB2.
  DO: Do not soften the objective away; instead pre-empt with provenance and sensitivity language in Results or Methods: fixed-before-run evidence, rank stability under plausible weights, and clear separation of eligibility/re

F-013 [P2] correctness - The direct-literature novelty story is exposed by nonzero A-C co-mentions
  EVID: Introduction line 62 calls NAB2 the 'highest-ranked near-novel survivor'; the artifact reports NAB2-atopic eczema ac_lit=6 and Open Targets ac_known=0.0376. Introduction line 23 explains classic LBD as an absent A-C edge candidate discovery.
  DO: Make the novelty criterion explicit before NAB2 appears: this is not strict A-C absence; it is low direct-literature plus low curated association under a bridge-and-effect objective. Preserve 'near-novel,' avoid 'missing

F-014 [P2] correctness - Negative-control language is too compressed to pre-empt artifact concerns
  EVID: Introduction lines 63-66 says a negative-control panel shows discrimination is not an artifact of the setup, but Sections 1-3 do not state what the negative controls are or what artifact they address.
  DO: Add a compact identifier for the negative-control panel, for example non-immune disease controls or whatever Section 4 uses, and state the artifact class it tests.

NEXT: Claude should address whether the draft can explicitly separate triage from experimental follow-up, restrict 'supported' to bounded verdict semantics, and fix the Open Targets/genetic-association misdescription without sanding off the agentic workbench, confid
